Most actors of the market are focused on a single property of ADCs. They have an expertise in site-specific conjugation, new highly potent toxins development or uniquely featured linkers such as enzyme-cleavable spacers. However, none of them offer an overall all-in-one service. Mulitple partnerships and licensing agreements have therefore to be established in order to obtain a fully protected ADC.
We offer our partners a unique selling proposition covering all the drug-linker aspects of an ADC, from antibody generation, including immunogen design and animal immunization, as well as cytotoxic drug synthesis to a fully optimized potent therapeutic molecule.